CRRTF (Crescita Therapeutics) GF Score: 22/100 (As of Aug. 03, 2026) — 51% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CRRTF Crescita Therapeutics Inc CRRTF
22 GF Score
Price $0.56
GF Value $0.50
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Crescita Therapeutics GF Score?

Crescita Therapeutics CRRTF 22 GF Score is 22 as of Aug. 03, 2026, which is 51% below its 10-year median of 45.00. GuruFocus rates CRRTF with a GF Score™ of 22/100 and a GF Value™ of $0.50 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Crescita Therapeutics has the GF Score of 22, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 4/10
3. Growth Rank : 2/10
4. GF Value Rank : 0/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes Crescita Therapeutics might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Crescita Therapeutics  (OTCPK:CRRTF) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.

Crescita Therapeutics GF Score Related Terms

CRRTF vs ZTS: GF Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Crescita Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescita Therapeutics GF Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Crescita Therapeutics's GF Score distribution charts can be found below:

* The bar in red indicates where Crescita Therapeutics's GF Score falls into.


CRRTF
22GF Score
Crescita Therapeutics Inc CRRTF
GF Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Score →
What does a GF Score of 22 mean?
Crescita Therapeutics (CRRTF) has a GF Score of 22 as of Aug. 03, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Crescita Therapeutics and its competitors. This is 51% below median its historical median of 45.00. Over the past decade, Crescita Therapeutics' GF Score has ranged from 16.00 to 64.00.
Is Crescita Therapeutics' GF Score too high?
Crescita Therapeutics' current GF Score of 22 is 51% below median its 10-year median of 45.00. Over the past 10 years, this metric has ranged from a low of 16.00 to a high of 64.00. Overall, Crescita Therapeutics has a GF Score™ of 22/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Crescita Therapeutics' GF Score compare to ZTS?
Crescita Therapeutics' GF Score of 22 can be compared against companies in the Drug Manufacturers industry. Historically, Crescita Therapeutics' own GF Score has ranged from 16.00 to 64.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Crescita Therapeutics and its competitors. Crescita Therapeutics's current GF Score is 22, which is 51% below median its own 10-year median of 45.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescita Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Crescita Therapeutics (CRRTF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.50, compared to a current price of $0.56 — trading 11.7% above its estimated fair value. The current GF Score is 22, which is 51% below median its 10-year median of 45.00. Crescita Therapeutics' overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Crescita Therapeutics (CRRTF), the current GF Score is 22 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Crescita Therapeutics (CRRTF) Overvalued in 2026?

Based on GuruFocus' analysis, Crescita Therapeutics stock appears to be overvalued. The current stock price of $0.56 is trading 11.7% above its estimated GF Value™ of $0.50. GuruFocus considers Crescita Therapeutics to be Modestly Overvalued.

Key valuation signals for CRRTF:

  • GF Score: 22 (51% below median its 10-year median of 45.00)
  • GF Value™: $0.50 vs. price of $0.56 (11.7% above fair value)
  • GF Score™: 22/100 with 5 warning signs

No single metric tells the full story. See the CRRTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Crescita Therapeutics Business Description

Address 2805, Place Louis-R-Renaud, Laval, QC, CAN, H7V 0A3
Crescita Therapeutics Inc is a commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada followed by USA and Rest of the world.
22GF Score

Get the complete analysis for CRRTF

GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price
$0.50
GF Value